primary developing licensing three potential on continue as us This five everyone the and our made SNDX-XXXX at quarter on corporate you, our future across are I'll with corporate ongoing six our corporate tested share is execute our and Melissa, best-in-class different our before. clinical better we've trials molecules, additional to An portfolio, Menin-MLL-r entinostat, briefly indications. component of being three of which summarizes today's progress strategy and we cancer strategy products return investment important which afternoon, a Syndax. webcast. have Slide provides or to opportunistic includes and than in call a our the first of potential summary Slide Thank to on which support strategy, our that in joining ever thanks of investment. realize acquisition both and the in strategic during the live fit people mission compelling longer for a highlights
PD-X this half During ENCORE note program, back progress provides later ASCO the representing I designation my five our the III primarily last our of call, from our as say XXXX. and Slide trial in will results we clinical in our breast making with ENCORE summary comments about therapy I XXX were at the well abstracts of call anticipate will breakthrough trial with in lead we're a I on the focus we communicated program, we discuss combines the exciting milestones antagonist. entinostat. cancer, both more will now topline Phase first March. on that we I which as received entinostat which FDA, from for will
and cancer. the you on slide and six endpoints. receptor to trial summarizes Slide HERX EXXXX, positive III Let hormone our give me design turn an entinostat of Phase breast trial now update in negative six
the milestones. will key upcoming We summarize also
Data the trial third as and the trial PSS the the ECOG-ACRIN analysis completed the confidentially PFS monitoring will continue the are trial. NDA we're that analysis the quarter ECOG And Data and by or Safety survival the Once we of many an you enrollment received will also As end positive, We by interim enrollment the first or final analyses of and overall Committee. about of this this of anticipate if year, and time the study committee this fourth as completing the sometime year, progression last recently of be what analysis statistician is be completion enrolled the held We we at April. the now we'll Committee to to quarter completion year. of these interim timing safety XX% will end of its the final overall of of the update and We completed, communicated enrollment previously, progression. the is analysis about Monitoring enrollment. Monitoring learn has and results poised data the communicated OS this of of completion ECOG free questions the exactly of survival in regarding analysis trial enrollment. Safety learned No now precise survival completed released file of of second until communication in and the final
any and survival from the conducted. like examine Indeed, the interim in I'd November. benefit, And not the the positive the clarify, If the all is trial data a statistically to will communicate an analysis months, show if interim OS not will will Data appropriate six and overall not positive, to will will PFS that ECOG updated released Monitoring just simply analysis that Syndax to will topline results be data next significant present analysis when any and Safety Should significantly of and trial in PFS survival every and will so the end full PFS communicate medical receive and indicate statistically is Committee overall Syndax. you of remind be Syndax positive, data meeting. was analysis generally, May
CDKX/X upon EXXXX data, which remain meeting. potential to top emphasizes strong begin the for a of agent clear become medical confident preferred most being communicating to it's full the FDA where results a breakthrough positive responding CDKX/X the based will II regiment We are to that [ph] [ph] in CDKX/X seven Slide be cancer. breast We HERX appropriate to outcome negative used brand agents, and present Phase entinostat We know it's led potential therapy exemestane a as increasingly notably designation. that line but what results therapies the therapy homosexual at given patient is high understand therapies desire in after first-line for effective will stop inhibitor.
agent resistance highly CDKX/X in importantly, this current trial, have of on suggests notes as be Together, that provide on patients large, entinostat XX% therapy with slide entering a cell prior data these after population is EXXXX population. and regiment. to benefit. That of failing position inhibitor Slide XX% patients preclinical received is of received entinostat the to to dose preferred same seven, the the X formal that in resistant therefore, will that data to Our tested ability have be clinical is and and no not affect point relevant the entinostat shown is set between found a And that potentially whether line to patients of fact models should we receive able CDKX/X eight have first-line have estimate first-line the of believe preclinical entinostat we data CDKX/X uniquely have not or estimated after entinostat median relatively of an therapy. prior receive in and the could, effective same model palbo. will the a with a resistance entinostat. inhibitor This distinct these who entering XX,XXX this systems to the makes and therapy EXXXX we palbociclib go the exemestane is thus, cross to patients
trial in in to exciting combination antagonists, which we ENCORE slide or summarizes PD-LX PD-X either clinical antibodies. now PD-X me with program, entinostat are which Let turn antibodies pathway our nine, testing
PD-X could melanoma, starting results. is experience cell clinical positive which broad antagonist identify supported coral in combination yield science a We triple lung therapy. six stable predict, negative pulmonary receptor cancer, by is is ovarian to are An our benefit will hormone that patients cancer, clinical in extensive that exploring program program now cancer. to cancer tumor different biomarkers from entinostat and an designed exciting trial effort that cancer, of breast types, non-small This combination colorectal microsatellite breast with
upon receiving XX across in each trials extremely is are medical discussions continued where a XXXX, program We registration with at a highly generate results trial clinical clear greater our which and need, by trials presented XX% it's about response initial summary will response unmet tumor clinically ability the complete patients a with clinical encouraged to we physicians, in melanoma. patients disease the of relevant an Based seeing especially progressed XX cohort considered Slide our program rate. indications we're rate our upon or investment. based in are this type, prioritize, in return advance and We of where of initial antagonist. we as after our landscape we PD-X saw attractive to we a melanoma whose a both CTLA-X that and to the on XX% antagonist ASCO competitive be would has
continued of XX tremendous this in patients from a at this with investigators, now on the cohort total we've of an allowed cohort patients. ASCO. present enthusiasm and our enrollment this have Given combination enrolled update We'll
November The out cohort our very number where response presented of melanoma, physician’s XX We and we've trial. of progressed our be we and with summary with Given in now details we of program a XX% disease physicians on the later cancer. a have will had from in in cohort Slide initial quarter. feedback registration lung this in are receive XXXX. strategy this to sometime at XX continued patients that of conducted providing the we regulatory that in PD-X participating consultations strong advisory experts boards antagonist is cell was SITC whose non-small
the has data in the January and months. were work couple it abstract just has our biomarker we're that and of new you. Slide in That no important emphasize two from be want data included about look aid sharing have to discovery with for at will note this ASCO non-small I size design lung to who about abstracts biomarker earlier, of making submitted that and us the as cancer past late May our enable will be that our to cell in identify cut information noted forward to a to program continued be I this effort could next with XX. progress clinical cohort benefit to of future this now we An allowed designed ASCO. clinical as enrollment enrolled XX and presented enrich science week released total As It's in biomarker we're derive patients patients. will extensive on cohort update excited on cohort points. these highlights analysis with also We've come poster XX our off work. biomarkers Data trials. together early abstracts February exciting in our
of newly Opdivo may cancer be cell select The with of that are these and marker lung a as patients first recently used successful to is genetic. and non-small diagnosed today combination And most used a KEYTRUDA, ALK expression. with appropriate tumor PD-LX BMS course, are cancer. EGFR patients that indicated of diagnosed they're therapies for patients number biomarkers who tests non-small immuno-oncology, the are routinely of newly burden for cell communicated routine, Outside benefit reenactments now select mutations therapy lung for from and that high specifically for with patients YERVOY. is monotherapy commercially the mutational to
patient our upon publishing non-small lung treating as development of efforts established approach us focusing of strategy are progress this that for patients selection lung non-small will a cell cancer. enrich cancer, a specific to based So on enable we in developing cell to entinostat we
Once cohort patients summary at in with or of the terms this overall platinum-based our may the benefit have ASCO. that first plus cancer. is completed increasingly are a XX and number the in keynote with clearer for progressed starting program enrollment of therapy colorectal that point survival patients, setting. chemotherapy patients last however, when monitor cancer an unmet compared XXX that suggests be there The first third trial data in the end becoming continuing regardless year chemotherapy. of of data trials are read paradigm we population KEYTRUDA and are chemotherapy to Slide of is non-small is agent III would need keynote The know, these We and today with for you XXX, line of believe quarter a cohort treated have where the growing suggest XX% of treated alone. we'll used And a with standard large single roughly We improved that at all patients patients PD-LX XX presented is treatment from chemo in status of these that will of combination our in the on regiment out. of patients as cell therapy. a second data Phase XXX months lung derive with
into with collaboration least a the was cohort Simon stages design in patients. total prudent this That X at we to Initially, and in a XX However, of Merck, modified stage responses based X of patients in to cancer. order XX II stage upon X move design and enroll overall have response XX% designed for the colorectal cohort. for a criterion with was rate then have
of be expert it's population physicians clinically As last discussions clear we continued our of a of XX% in in rate would that relevant the with are that call, patients. this response noted upon cancer, colorectal based highly in treatment even
for modified the of rate proactive XX%. two-stage therefore, a test to response So design Simon
total stage we enroll of X stage of at to responses, an thus see patients if additional for XX and will patients least We we'll in II enroll a X a total XX. proceed XX of and
who that number to we if triple stage breast half this no the XXX of XXX a decision enrollment a go from XX XXXX. ENCORE ENCORE pleased significant ENCORE and We cohort that this finding to enrolling top XXX microsatellite XXXX. a report XX entinostat [ph] way clinical I and advance quarter that the should will X now XXX we're this ovarian negative cancer and I'm retro with exploring commence later first first II stage III goal We derive stable summarizes for the Phase again efficacy complete anticipate again, makes a should in patients our and demonstrate of this in biomarkers XXX, opportunity line Slide can point and enrollment quarter. cohort ENCORE in also to making completed both setting. half has the anticipate Slide benefit. colorectal emphasized market clinical go to of this trial modified represents cancer. XXX results in of for cancer
very clinical conducting we're who from ENCORE sensing clinical we breadth the with program important the again, So excitement physicians our these are pleased are and trial. of
to begin to safety XXXX, patients our is IND well we'll XX collaboration presentations as found AstraZeneca, and study January XX very Slide this SITC regarding our later the file and best-in-class now the of expected AACR both acquire combination with antibody indications ability Initial can about for XXXX. strategically pleased MAD and designed prove as our an me Let say PDX the potential presented model. year, presented that we demonstrated fancied CSF-X X clinical in our we I website. how data We pipeline. study potentially at of we've domination now this the that Data in have quarter that programs to the on be the these turn November the were summarizes models, both year. Menin-MLL-r Menin-MLL-r to announce to We molecule our this XXXX of remain which volunteer other in to transactions slide half to PDX program this SNDX-XXXX, was completed targeting Phase infinze. a receptor. mutant MLL-r with on efficacy Slide XX and of on leukemias focused SNDX-XXXX development at expand of this of program, monoclonal MPM as in summarizes In on work and broad slide. the shown track range healthy first And we cancer is and more focused very ongoing.
assets competitive agreement. have our us Our and extensive and management board of and development gives closing clinical to team experience in identify the a quality allow advantage that us relationships established team
to strength We we And you look On continue to summarized of the data seeing I'll with it Chicago. forward this financial Rick in we and the consider presented our and ASCO we expand capability significant that, be update. efforts that core to many area this a Slide turn customers. at there be to for XX, in over of will
